UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) JAIM IMMUNOTECH INC. Presentation- “Ampligen - Immunology for a better future”.ĪIM ImmunoTech Announces Addition of Single-Agent Ampligen Arm to Cancer Center’s Ongoing Study in Cancer Patients with COVID-19 Equels Participates in Fireside Chat with Ascendiant Capital Markets Analyst Ed Woo Presentation- “Ampligen – Company Presentation – May 2021”.ĪIM ImmunoTech CEO Thomas K. Presentation at the ESWI conference dated December 6, 2021.ĪIM ImmunoTech Announces Clinical Trial Agreement for a Phase 2a Human Challenge Trial of Ampligen as a Potential Intranasal Prophylaxis Against Respiratory VirusesĬompany Presentation dated September 2021.ĪIM ImmunoTech?s Ampligen Featured in Peer-Reviewed Journal Cancers as a Potential Therapy for Cancer Patients with SARS-CoV-2 The Netherlands Grants AIM a Patent for Ampligen as a Cancer Therapy for Use in Combination with Checkpoint Blockade InhibiĪIM ImmunoTech Announces Two Year Extension of Agreement with Shenzhen Smoore Technology Limited to Develop and Test a New Inhalation Delivery Device for Ampligen Announces plans to conduct Phase 1/2 clinical study incorporating new inhalation techno Janupresentation: “Ampligen: A General Overview and the Plan for ME/CFS & Long Covid”ĪIM ImmunoTech Announces Publication of Positive Results from Phase 1/2 Study of Intraperitoneal Chemo-Immunotherapy in Advanced Recurrent Ovarian Cancer Chemokine-modulating IP chemo-immunotherapy combination demonstrated to be well tolerated, and a FDA to Advance its Phase 2 Study of Ampligen? for the Treatment of Locally Advanced Pancreatic Cancer Data seen to date indicates that Ampligen? (rintatolimod) could be a potential effective maintenĪIM ImmunoTech Announces Strategic Sale of New Brunswick, New Jersey Facility to Allocate Additional Resources to Advance PipelineĪIM ImmunoTech Appoints Robert Dickey, IV as Chief Financial Officer Industry veteran and financial and strategic leader with deep capital markets and business development transactional expertise across life science and medical device companies AIM ImmunoTech Secures New State-of-the-Art Facility for Product Development and Testing Company enters into a lease agreement with the state-supported New Jersey Bioscience Center at North Brunswick, one of the nation’s leading business incubators dĪIM ImmunoTech Provides Progress on Advancement of Ampligen? Clinical Development Program for the Treatment of Pancreatic Cancer - Ampligen? (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotheĪIM ImmunoTech Receives IND Clearance from the U.S.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |